BridgeMD
TRAP study: Testosterone for Androgen Receptor Polymorphism.
EU CTIS ID: 2024-510596-37-01
What this study is testing
To determine whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes (COCs) obtained after ovarian stimulation by more than 1.5 in patients with low ovarian reserve and androgen receptor polymorphism undergoing intracytoplasmic sperm injection (ICSI).
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with low ovarian reserve according to Bologna criteria: at least two of the following three: ○ Age equal to or greater than 40 years. ○ Previous cycle with less than 4 oocytes retrieved. ○ Low ovarian reserve markers (antral follicle count <5-7; AMH <0.5-1.1 ng).
- 10. Muestra seminal procedente de eyaculado.
- 11. Ability to comply with the study protocol.
- 12. To have given their written consent.
- 2. Carriers of the androgen receptor polymorphism: between 22 and 24 CAG repeats.
- 3. Body Mass Index (BMI) less than 32.
You likely can't join if
- 1. Non-compliance with instructions or non-formalization of informed consent.
- 2. Concurrent participation in another study.
See the full eligibility criteria
- Patients with low ovarian reserve according to Bologna criteria: at least two of the following three: ○ Age equal to or greater than 40 years. ○ Previous cycle with less than 4 oocytes retrieved. ○ Low ovarian reserve markers (antral follicle count <5-7; AMH <0.5-1.1 ng).
- 10. Muestra seminal procedente de eyaculado.
- 11. Ability to comply with the study protocol.
- 12. To have given their written consent.
- 2. Carriers of the androgen receptor polymorphism: between 22 and 24 CAG repeats.
- 3. Body Mass Index (BMI) less than 32.
- 4. Indication for in vitro fertilization.
- 5. Presence of both ovaries.
- 6. Absence of ovarian cysts.
- 7. Absence of endometriosis.
- 8. Karyotype and normal fragile X study.
- 9. Absence of severe male factor.
- 1. Non-compliance with instructions or non-formalization of informed consent.
- 2. Concurrent participation in another study.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.